Exposure to HFpEF with cardiorenal syndrome, via mouse models or human patient serum, significantly increased renal interstitial fibrosis (1.9-fold; P<0.05) and endothelial-mesenchymal transition.
Endothelial-mesenchymal transition plays a plausible role in the pathophysiology of HFpEF with cardiorenal syndrome, representing a potential therapeutic target.
p-value: p=<0.05
Background: The management of clinical heart failure with a preserved ejection fraction (HFpEF) is often complicated by concurrent renal dysfunction, known as the cardiorenal syndrome. This, combined with the notable lack of evidence-based therapies for HFpEF, highlights the importance of examining mechanisms and targetable pathways in HFpEF with the cardiorenal syndrome. Methods: HFpEF was induced in mice by uninephrectomy, infusion of d -aldosterone (HFpEF; N=10) or saline (Sham; N=8), and given 1% NaCl drinking water for 4 weeks. Renal fibrosis and endothelial-mesenchymal transition (endo-MT) were evident once HFpEF developed. Human aortic endothelial cells were treated for 4 days with 10% serum obtained from patients with chronically stable HFpEF with the cardiorenal syndrome (N=12) and compared with serum-treated human aortic endothelial cells from control subjects (no cardiac/renal disease; N=12) to recapitulate the in vivo findings. Results: Kidneys from HFpEF mice demonstrated hypertrophy, interstitial fibrosis (1.9-fold increase; P <0.05) with increased expression of endo-MT transcripts, including pdgfrβ (platelet-derived growth factor receptor β), snail, fibronectin, fsp1 (fibroblast-specific protein 1), and vimentin by 1.7- ( P =0.004), 1.7- ( P =0.05), 1.8- ( P =0.005), 2.6- ( P =0.001), and 2.0-fold ( P =0.001) versus Sham. Immunostaining demonstrated co-localization of CD31 and ACTA2 (actin α2) in kidney sections suggesting evidence of endo-MT. Similar to the findings in HFpEF mice, comparable endo-MT markers were also significantly elevated in human aortic endothelial cells treated with serum from patients with HFpEF compared with human aortic endothelial cells treated with serum from control subjects. Conclusions: These translational findings demonstrate a plausible role for endo-MT in HFpEF with cardiorenal syndrome and may have therapeutic implications in drug development for patients with HFpEF and concomitant renal dysfunction.
Valero‐Muñoz et al. (Thu,) conducted a other in Heart failure with a preserved ejection fraction (HFpEF) with cardiorenal syndrome (n=42). d-aldosterone infusion (mice) / HFpEF patient serum (human cells) vs. Saline (mice) / control subject serum (human cells) was evaluated on Renal interstitial fibrosis and expression of endothelial-mesenchymal transition (endo-MT) transcripts (p=<0.05). Exposure to HFpEF with cardiorenal syndrome, via mouse models or human patient serum, significantly increased renal interstitial fibrosis (1.9-fold; P<0.05) and endothelial-mesenchymal transition.